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Abstract— Aims: The aim of the study was to explore whether the concept of heavy substance use over time can be used as definition
of substance use disorder.Methods: Narrative review. Results: Heavy use over time clearly underlies the neurobiological changes asso-
ciated with current thinking of substance use disorders. In addition, there is evidence that heavy use over time can explain the majority
of social problems and of burden of disease (morbidity and mortality). A definition of substance use disorders via heavy use over time
would avoid some of the problems of current conceptualizations, for instance the cultural specificity of concepts such as loss of control.
Finally, stressing the continuum of use may avoid the high level of stigmatization currently associated with substance use disorders.
Conclusion: ‘Heavy substance use over time’ seems to be a definition of substance use disorders in line with results of basic research
and epidemiology. Additionally, it reduces stigmatization. This approach should thus be further explored.
INTRODUCTION
In the last half century, a variety of definitions and concepts
for what we now call ‘substance use disorders’ have been pro-
posed in international classification systems (Room, 1998),
starting with the now infamous split in the late 1950s by the
WHO between drug addiction and drug habituation, with alcohol
and tobacco in the latter category (World Health Organization,
1957; http://whqlibdoc.who.int/trs/WHO_TRS_116.pdf). At that
time, in accordance with political orthodoxy, the WHO Expert
Committee on Addiction-Producing Drugs distinguished between
the addiction-producing illegal drugs with the characteristics of
compulsion, tolerance, psychological and physical dependence
and a detrimental effect on the individual and society, in contrast
to the habit-forming drugs, including alcohol and tobacco, with
the characteristics of a desire to take the drug for individual well-
being, little or no tendency to increase the dose, some degree of
psychological but no physical dependence, and little or no (if
any, they would be primarily on the individual) detrimental
effects (World Health Organization, 1957, pp. 9–10). As con-
sequence, the Committee concluded that for illegal drugs,
there should be strict national and international control, while
warning labels and some national control measures should
suffice for alcohol and tobacco; but ‘any warning concerning
habituation should not carry the stigma of addiction’ (World
Health Organization, 1957, p. 14).
Our view on alcohol and tobacco as dependence-producing
drugs and their impact on the individual and society relative to
illegal drugs has since changed dramatically (see for instance
Nutt et al., 2010). In both major classification systems current-
ly used (World Health Organization, 1992; American
Psychiatric Association, 2000) dependence has been defined
as a syndrome of physiological, behavioural and cognitive
phenomena, which lead to loss of control over use. Several cri-
teria must be fulfilled for a diagnosis of dependence, and these
criteria are the same for all psychoactive substances. The new
revision of one of the systems, DSM-5, abandons the term ‘de-
pendence’ in this established meaning (see below). Instead it
substitutes ‘use disorder’, defined in terms of eleven criteria in-
cluding physiological, behavioural and cognitive elements, as
well as consequences of criteria, any two of which qualify for a
diagnosis (American Psychiatric Association, 2013).Theories
about habituation and compulsion and the underlying neural
levels have also changed (Everitt and Robbins, 2005).However,
there is still no binding international agreement on control of
alcohol (Room et al., 2008; Rehm and Room, 2009), and thus
some of the ideas about distinguishing between drugs in terms
of prohibition and control based on outmoded ideas of relative
dependence-propensity and harmfulness continue to persist.
The example of the 1957 WHO definition is given as illustra-
tion of two points: (a) definitions of disease and disease cat-
egories change dramatically even over a short time and (b) they
are subject to various social, economic and political influences
(Neuman et al., 2005; Frances, 2013), despite repeated calls for
more evidence-based definitions of substance use disorders and
policies (Wood et al., 2010). These points are not only true for
substance use, but also for definitions and policies in the wider
field of mental health, as the recent debate on DSM-5 shows
(Frances, 2013), or in medicine as a whole. Obviously, it is hard
to define normal vs. diseased, and various interests push the
definitions in different directions. However, there is a need for
defining disease for a variety of reasons, not least because of its
associated consequences such as individually experienced dis-
ability, loss of functioning and lack of well-being (Broome,
2004), as well as societal costs and lack of productivity (e.g.
Rehm et al., 2007a) and health care costs.
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THE RELATIONSHIP BETWEEN HEAVY USE,
SUBSTANCE USE DISORDERS AND CONSEQUENCES
Given the relatively rapid fluctuations in definitions and termin-
ology (once characterized by Bruun, 1971, as moving ‘compul-
sively from one model to another’), we feel free to propose to
define all substance use disorders, i.e. alcohol, tobacco, illegal
drugs and prescription opioid use disorders, completely differ-
ently: as heavy use over a period of time (see Li et al., 2007b;
Saha et al., 2007, for earlier reflections on use patterns as part
of the definition of use disorders). The main arguments can be
characterized in the following five statements:
(1) Heavy use over time is responsible for the changes in
the brain and other physiological characteristics of sub-
stance use disorders
The use of psychoactive substances has short- and long-term
impacts on the brain. Short-term effects can lead to intoxica-
tion or even death via overdose (for a more elaborate tax-
onomy of harm based on short- vs. long-term use see Fischer
et al., 1997), and long-term heavy use leads to changes in the
brain that are characteristic of what is currently covered by
terms such as ‘addiction’, ‘dependence’ and ‘substance use
disorders’ (conceptually: Leshner, 1997; Volkow and Li,
2005; for common classification systems: World Health
Organization, 1992; American Psychiatric Association, 2000).
In a recent overview where the authors were charged with
summarizing the neurocognitive effects of addiction vs. heavy
use for the Dutch Medical Research Council, they ended up
concluding that any such distinction is impossible to make in
the current literature, because there are no studies on neural
effects of substance dependence without prolonged heavy use
(Wiers et al., 2012). Thus, the effect of prolonged heavy use
on the brain appears to be at least largely overlapping if not
identical with what is called ‘addiction’ or ‘substance use dis-
orders’. In addition, heavy use over time leads to other physio-
logical changes such as in skin conductance level (Kaplan
et al., 1985).
(2) Heavy use is responsible for intoxication and for the
withdrawal and tolerance phenomena regarded as central
to current definitions of addiction or dependence
During the deliberations on the new DSM-5, the website of
the American Psychiatric Association featured the following
explanation for changes in the new concept: (as it is no longer
on the website, cited after Rehm et al., 2011a).
There was general agreement that ‘dependence’ as a label
for compulsive, out-of-control drug use has been problematic.
It has been confusing to physicians and has resulted in patients
with normal tolerance and withdrawal being labelled as
‘addicts.’ This has also resulted in patients suffering from
severe pain having adequate doses of opioids withheld
because of fear of producing ‘addiction’. Accordingly, the
word ‘dependence’ is now limited to physiological depend-
ence, which is a normal response to repeated doses of many
medications including beta-blockers, antidepressants, opioids,
anti-anxiety agents and other drugs. The presence of tolerance
and withdrawal symptoms is not counted as symptoms to be
counted for the diagnosis of substance use disorder when oc-
curring in the context of appropriate medical treatment with
prescribed medications.
Tolerance and withdrawal, criteria for substance depend-
ence in both major classification systems, are natural physio-
logical reactions to prolonged use above a certain dose of
psychoactive substances, and they occur whether the sub-
stance was prescribed by a doctor or not. Thus, it makes no
sense to assign any diagnostic value to the origin of the sub-
stance. The point here is that continued heavy use of psycho-
active substances produces physiological reactions that are key
in our current concept of substance use disorders. Whether
such states are reversible or not depends on a multitude of
factors; it is possible to overcome substance use disorders (e.g.
the experiences with heroin use disorders of Vietnam veterans,
Robins, 1993), while on the other hand prescribing psycho-
active substances may create long-term heavy use requiring
treatment for opioid use disorders (see, for example, the high
correlations between medical use and non-medical use or sub-
stance use disorders for prescription opioids, Fischer et al.,
2012).
(3) Heavy use over time is responsible for the main social
consequences of substance use disorders, such as pro-
blems in fulfilling social roles
Heavy use over time is a primary driver of the social harms
from use of psychoactive substances. Illustrating this from
alcohol, an Australian study of harms to family members and
friends from another’s drinking found such harm to be wide-
spread in the population, with 28.5% of adults reporting such
harm in the last year. The person whose drinking had affected
them most adversely was described on average as drinking 13
drinks on an occasion when drinking heavily, and drinking 5
or more drinks at least 3 times a week (Laslett et al., 2010,
2011).
It is also well recognized that heavy use of alcohol over
time potentially adversely affects work performance (Gmel
and Rehm, 2003). An analysis of self-reported problems from
drinking in a US national sample of adult males found that
work problems, family problems and criminal-law problems
were all most strongly predicted by the regular drinking of five
or more drinks on an occasion (Gmel et al., 2000).
(4) Heavy use over time is responsible for the majority of
the substance-attributable burden of disease and mortality
There are clear dose–response relationships to disease and
most health harm for both alcohol and tobacco (Corrao et al.,
2004; Doll and Bradford Hill, 2004; Rehm et al., 2010a). As a
result, in recent analyses for alcohol, Rehm and colleagues,
pooling the results of all EU countries, found that >77% of the
net mortality burden (i.e. after subtracting the beneficial
effects of alcohol consumption on ischaemic disease and dia-
betes from the overall alcohol-attributable burden—Rehm
et al., 2010a) and 67% of the overall mortality burden attribut-
able to alcohol were due to heavy drinking, defined as >60
g/day for men, and >40 g/day for women (Rehm et al., 2013).
Using an independent analysis for alcohol dependence, about
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71% of the net burden and 62% of all the harmful
alcohol-attributable mortality burden were caused by alcohol
dependence (Rehm et al., 2013; Roerecke and Rehm, 2013).
As alcohol dependence is clearly characterized by heavy
drinking (Dawson et al., 2008; Schuckit, 2009), one plausible
potential explanation for these results would be that the
pathway by which alcohol dependence causes mortality is via
heavy drinking. Obviously, this pathway should be substan-
tiated in further research using adequate statistical method-
ology such as structural equation modelling (Muthén, 1984).
For other psychoactive substances, similar associations can
be made. For tobacco, there are clear dose–response relation-
ships to disease and most harm (e.g. Khuder, 2001), and for
illegal drugs, heavy use is often defined by high frequency of
use, such as daily or almost daily use. For instance, for canna-
bis, daily use over time has been linked to a number of nega-
tive health and other outcomes, and has thus been highlighted
as a public health concern (Fischer et al., 2011; http://www.
emcdda.europa.eu/publications/thematic-papers/
daily-cannabis-use).
(5) Heavy use over time as a definition better fits the em-
pirical data and may diminish stigmatization and avoids
pointing attention away from highest-risk categories
One possible advantage of characterizing substance use disor-
ders in this way would be that such a definition is less stigma-
tizing than the label of addiction. The importance of
stigmatization has already been highlighted in the citation
from the WHO Expert Committee above (World Health
Organization, 1957), and recently summarized empirical re-
search found alcohol use disorders to be the most stigmatized
mental disorders, closely followed by illegal drug use disor-
ders (Schomerus et al., 2011; see also Schomerus et al.,
2013). A comparative study in >10 countries, including low
and mid-income countries, found drug use disorders more
stigmatized than alcohol use disorders, but overall the high
stigmatization of substance use disorders was corroborated in
this study as well (Room et al., 2001).
A definition based on heavy use over time may constitute
an improvement with respect to stigmatization, as it is de facto
just one end of a continuum of use, and as most people in
Europe use alcohol, they could place themselves on the con-
tinuum (World Health Organization, 2011; Shield et al.,
2012); such a definition might lead substance use problems to
be perceived similarly as hypertension, hyperuricemia or ele-
vated blood sugar; i.e. as a sign to change lifestyle or to start
using medication (Nutt and Rehm, Unpublished manuscript).
Thus, conceptualizing the disorder in terms of heavy use over
time on a continuum of use implicitly points to reduction of
use, including but not limited to abstinence, as a solution.
Such solutions are not that clear from current definitions of
substance use disorders. It should be noted that while reduc-
tion of use and abstinence are linked to clear benefits in terms
of morbidity and mortality (Rehm and Roerecke, 2013; Rehm
et al., 2013, for alcohol; Popova et al., 2009, for tobacco; Hser
et al., 2001 for illegal drugs), some of the health consequences
may be irreversible.
We believe that redefining substance use disorders in terms
of heavy use over time will also avoid pointing attention away
from those most at risk of harm from their substance use.
Consider tobacco dependence as an example. First, there seems
to be no added value in using a term like tobacco dependence
instead of smoking a pack of cigarettes for the past year except
that we stigmatize these smokers further. Second, as surveys
show, the prevalence of dependence as defined by DSM-IV is
often similar to the prevalence of smokers smoking 20 cigar-
ettes or more (Lessov et al., 2004; Loukola et al., 2008; John
et al., 2009); however, the correlation between dependence and
number of cigarettes smoked is commonly low, i.e. <0.5, indi-
cating that heavy smokers and dependent smokers only overlap
to a limited extent (Kawakami et al., 1999; Strong et al., 2003;
DiFranza et al., 2010). To give an example, Loukola et al.,
(2008) found that 48% in their sample of Finnish twins were
dependent by DSM-IV criteria and 50% smoked heavily (≥20
during heaviest smoking period or ≥40 on a single day), but the
correlation between DSM-IV nicotine dependence and preva-
lence of heavy smoking was only r = 0.44. Thus, many heavy
smokers were not dependent. To give another example from
our ALICE RAP calculations: in the German Epidemiological
Surveys of Substance Abuse (ESA) from 2009 (Kraus and
Pabst, 2010), 51% of those smoking 20 or more cigarettes were
not dependent by DSM-IV criteria. In other words, those
heavy smokers did not endorse at least three of the seven
criteria, for whatever reason.
However, what does this mean for health risks? Are heavy
smokers who are not classified as dependent less at risk for
disability or dying from lung cancer (Lim et al., 2012)? Do
they have a higher chance to quit smoking? We have no evi-
dence for this, and some evidence to the contrary, i.e. heavy
use predicting later abstinence better than dependence accord-
ing to DSM-IV criteria (Hendricks et al., 2008). Thus
Occam’s razor, i.e. the principle of parsimony stating that
among competing explanations the explanation with the
fewest assumptions should be selected, as well as the stigma-
tization argument would suggest simply using the criterion of
heavy use, which has proven strong links to tobacco-related
health harm. Regarding the stigmatization argument, it seems
that the tobacco field is a prime example of how public
health-relevant ‘addictive’ behaviour can be changed without
labelling people as mentally ill (Frances, 2013).
For other substances, we have similar phenomena. Each
survey conducted without any pre-screening of respondents
shows a number of people who qualify for alcohol dependence
in any given year with low average consumption of one drink
or less and/or few or even no heavy drinking occasions
(Caetano et al., 1997; Caetano and Cunradi, 2002; Rehm
et al., 2008; in a different age group: Holly and Wittchen,
1998), or people who qualify for cannabis dependence having
smoked cannabis <10 times in the last year, and never more
than one joint per occasion (see also the examples of Room,
1998). People with such a profile of use clearly are not of
much concern to public health, and neither are they in need of
medical interventions.
Another example from alcohol use disorders may also help
to justify the term heavy use over time as conceptually more
adequate. Consider the following example: the two most
recent surveys for alcohol use disorders revealed a 12.5%
prevalence of alcohol dependence in Latvia (Snikere et al.,
2011) and <0.5% in Italy (de Girolamo et al., 2006, using
standard survey methodology—Composite International
Diagnostic Interview CIDI; see Rehm et al., 2005, 2012, for
background on methodology and a European overview of
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prevalence rates). Even if we allow for methodological pro-
blems with the Italian estimate, as it was based on the World
Mental Health survey (Grant et al., 2007), which at the time
asked dependence questions only if the respondent had previ-
ously answered affirmatively to the abuse criteria, other evi-
dence from Italy would suggest prevalence of alcohol
dependence at most 1/5 to 1/10 that of Latvia (Scafato et al.,
2005). If we look at the per capita consumption of the two
countries for 2010, we find a recorded consumption of 6.1 for
Italy and 9.8 for Latvia, with unrecorded consumption being
estimated at an additional 1.4 for Italy and 1.8 for Latvia (http
://www.who.int/substance_abuse/activities/gisah/en/). Thus,
the overall drinking level is quite similar and nothing would
suggest a 5- to 10-fold difference in alcohol dependence
prevalence. However, the drinking patterns are different, with
Latvia showing a more harmful drinking style characterized
by irregular heavy drinking occasions (Popova et al., 2007;
World Health Organization, 2011), which has been shown to
lead to a higher disease burden (Rehm et al., 2007c).
Liver cirrhosis rates, often used as indirect indicator for de-
pendence, differ between the two countries, with age-standardized
rates for 2008, the last year available in the WHO data bank
(http://www.who.int/healthinfo/global_burden_disease/estimates_
country/en/), being 6.8 per 100,000 for Italy and 15.3 per
100,000 for Latvia. If we look into average heavy drinking
rates, the following picture emerges: at a cut-off of 60 g pure
alcohol per day, we would have a prevalence of 3.5% in Italy,
and 8.5% in Latvia, and with a cut-off at 80 g 1.5 and 4.6% for
Italy and Latvia, respectively (prevalence of heavy drinking
calculated by triangulating survey and per capita information:
Rehm et al., 2007b, 2010b; Kehoe et al., 2012; assuming that
80% of the sold alcohol is consumed). Even though the
average drinking rate may not be the most meaningful alcohol
consumption statistic for Latvia, as it is composed of fewer
drinking occasions with much higher drinking per occasion
(see below), all the resulting ratios between both countries are
much closer to each other and the liver cirrhosis mortality ratio
than to the dependence figures. We believe that a better ex-
planation of the divergent dependence rates are cultural differ-
ences and norms, which would prescribe that in Italy one
would not traditionally admit to losing control over one’s
drinking, whereas losing control may be the very reason why
many Latvians drink heavily (Room, 2006, 2007). As a result
questions about control and other psychological criteria in
DSM-IV or ICD 10 tend to be answered differently, even with
the same underlying behaviour (Room et al., 1996; Room,
2006; Rehm et al., 2012). Differences in criteria endorsement
could also be shown with respect to age (Miller et al., 1991;
Saha et al., 2006; Pabst et al., 2012).
ATTEMPTS AT INTEGRATING USE INTO THE
SUBSTANCE USE DISORDER CONCEPT
Several nicotine dependence screening instruments, of which
the Fagerström Test for Nicotine Dependence (FTND, just
re-named Fagerström Test for Cigarette Dependence;
Heatherton et al., 1991) is the most often used, already include
smoking quantity as a central item, and are therefore highly
correlated with use measures (Park et al., 2012). Similarly, one
of the most widely used screening instruments in the alcohol
field, the Alcohol Use Disorder Identification Test (AUDIT)
has three questions on use (sometimes used on their own as a
screening measure, the AUDIT-C: Bush et al., 1998), which
determine to a large extent whether people are scored positive-
ly or not (Babor et al., 2001; Gmel et al., 2001). Thus in a
Swedish population study (Hradilova Selin, 2006), 71% of the
positive scores of those scoring 8+ (the usual cut-off ) on the
AUDIT as a whole were derived from the AUDIT-C. Though
it was initially not intended as such, the AUDIT has commonly
come to be ‘viewed as screening for alcohol dependence’
(Hradilova Selin, 2006). Frequency of use as indicator of heavy
use is part of the WHO Alcohol, Smoking and Substance
Involvement Screening Test (ASSIST, WHO ASSIST Working
Group, 2002).
Also, in the instructions of several versions of the CIDI,
there are filter variables for only asking questions on substance
use disorders above a certain threshold of use (e.g. M-CIDI:
Wittchen et al., 1998). Finally, there have been numerous
attempts to integrate heavy use indicators into the criteria for
substance use disorders statistically, e.g. via item-response
theory driven analyses, usually with the result that such indica-
tors fit similarly to the current criteria (for alcohol Li et al.,
2007a,b; Borges et al., 2010; Saha et al., 2010; for cannabis:
Piontek et al., 2011).
HOW TO DETERMINE THRESHOLDS?
The population distribution of psychoactive substance use is a
continuum (for example Rehm et al., 2010b), with most
people abstaining for their lifetime from any given substance
(for alcohol, see Shield et al., 2013; for a general overview of
global exposures, see Lim et al., 2012). In this sense it will be
somewhat arbitrary to define thresholds and cut-points for
heavy use. Is somebody who drinks 60 g of pure alcohol on
average a day a non-heavy user, while somebody who drinks
70 g a heavy user? Applying an exact threshold to a continuum
is arbitrary, but we need such thresholds as many systems in our
society are built on them (such as treatment decision-making
and disorder codes for reimbursement of interventions).
For all psychoactive substances we suggest two thresholds:
one for so-called brief interventions, which consist of advice
to cut down with motivational support (Agerwala and
McCance-Katz, 2012), and one for formal therapy, either psy-
chosocial or pharmaceutical or both. While we will not give a
list of such thresholds for all substances in this piece, we illus-
trate their construction with two examples: tobacco and alcohol.
Table 1 illustrates the relationships between numbers of
cigarettes smoked (current) and dependence diagnosis in the
past 12 months, based on four different surveys from Germany,
the UK and Switzerland (part of the ALICE RAP Project).
Again we see the phenomenon that dependence is prevalent
already at low levels of cigarettes per day, but that there is also a
clear dose–response relationship.
There is consensus that brief interventions should be given
to all smokers, irrespective of status of dependence or smoking
use disorders (http://www.nice.org.uk/nicemedia/live/11375/
31864/31864.pdf). For formal therapy associated with heavy
smoking, we suggest a cut-off of 10 cigarettes/day and more, as
virtually all randomized clinical studies and thus our knowledge
regarding effectiveness of interventions are restricted to this
group. However, if a smoker wants to quit, therapy should be
offered.
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For the negative consequences of alcohol consumption, for
example alcohol-related cancers, there is no level of consump-
tion that is risk free. Australian guidelines to reduce the health
risks from drinking alcohol reported a lifetime risk of an
alcohol-related death as nearly 1 in 100 for both men and
women at a consumption of 20 g/day, increasing to about 4 in
100 at 40 g/day (National Health Medical Research Council,
2009). At a population level, and accounting for potential
reductions in the risk of ischaemic events, any alcohol con-
sumption above 10 g pure alcohol on average per day is asso-
ciated with higher overall mortality (Rehm et al., 2011b). So,
from a public health point of view, recommendations for brief
interventions for more than one drink daily on average could
be justified. In addition, for alcohol, there are clear indications
that patterns of drinking are important, most importantly the
frequency of heavy drinking occasions. Thus, drinking 10
drinks 3 days a week is more harmful than drinking 5 drinks
6 days a week (Rehm et al., 2006).
There have been attempts to define thresholds based on the
AUDIT (see above), with different thresholds being proposed
for brief interventions and for referral to formal treatment
(Babor et al., 2001). Analogous thresholds can be justified for
the already mentioned consumption items of the AUDIT, the
AUDIT-C (Dawson et al., 2012): average frequency, average
quantity and frequency of heavy drinking occasions. Future re-
search will have to determine the best exact models incorporat-
ing both average consumption and heavy drinking occasions.
Guidelines of the European Medicines Agency might imply a
threshold for brief interventions of >40 g pure alcohol on
average per day for men and 20 g for women; or alternatively
at two 60 g (men)/48 g (women) drinking occasions per week.
Also a threshold of 80 g of average daily consumption for at
least 6 months for men, and 50 g for women, could serve as a
basis for formal therapy (European Medicines Agency, 2010).
The point here is that establishing meaningful consumption
criteria for brief intervention or formal therapy is possible.
More research and a formal process for integrating the evi-
dence are necessary, as it has been done for hypertension in
several countries such as the US (http://www.nhlbi.nih.gov/
guidelines/hypertension/jnc7full.pdf).
CONCLUSIONS
We have given evidence to redefine the concept of substance
use disorders in terms of heavy use over time. Such a concept
would incorporate all the necessary elements for decisions on
prevention and treatment, and it would avoid culturally relative
arbitrary definitions in terms of loss of control or of failure to
fulfil social roles. It seems we do not need any other construct
to describe the phenomenon of heavy use over time, such as
the term addiction. Establishing heavy use over time as the
relevant entity may also contribute to a de-stigmatization of
people who use psychoactive substances heavily. It would
also help to initiate lifestyle changes and treatment and other
interventions for heavy use earlier in time, e.g. with brief inter-
ventions in primary health care (e.g. Kaner et al., 2007, for
alcohol; Humeniuk et al., 2012, for illicit drugs; Doran et al.,
2006, for tobacco). It may also help to close the treatment gap
for substance use disorders by lowering stigmatization, espe-
cially for alcohol (Rehm et al., 2013).
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